Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Domestic pharmaceutical manufacturing is key to outcompete China.

Garcia and Beverly 21 (Lynne Chandler Garcia is an Assistant Professor of Political Science at the United States Air Force Academy. Michael Beverley is the Vice-Chair and Co-Founder of OneMedical Grouph; “Reinvigorating Puerto Rico’s Pharmaceutical Industry: A U.S. Security Imperative”; Centro Journal; Vol. 33 Issue 2; Summer 2021; https://web.s.ebscohost.com/ehost/detail/detail?vid=0&sid=19ad5725-03b5-438b-b2fa-185df1e64773%40redis&bdata=JnNpdGU9ZWhvc3QtbGl2ZSZzY29wZT1zaXRl#AN=152480710&db=a9h)

COVID has demonstrated that pandemics and medical crises are national security concerns for which the U.S. must be prepared. The U.S. must regain its ability to independently manufacture enough pharmaceuticals to meet U.S. 62 centro journal • volume xxxiii • number ii • summer 2021 domestic needs and break its reliance on other nations. In doing so, the U.S. will need to follow China’s lead and create incentives for pharmaceutical companies to return to American soil. Tax breaks, grants, and creating special economic zones are possible methods to support the U.S.-based pharmaceutical industry. In April 2020, President Donald Trump signed an executive order requiring federal agencies to buy essential drugs and medical products from U.S.-based manufacturers rather than from overseas. Additionally, Congress passed the CARES Act, an omnibus bill that includes provisions to secure the American supply chain of pharmaceuticals and empowers the Biomedical Advanced Research and Development Authority (BARDA) to work with private firms to produce COVID-related treatments. Through Operation Warp Speed, BARDA is already providing funding to companies researching COVID treatments that have a U.S. base or extensive American operations. While this is a step in the right direction, it is not enough to return manufacturing to American soil. The U.S. must jump start manufacturing in locations that have a history of pharmaceutical production and many of the resources in place—Puerto Rico might fit this requirement.

Sign in to recut, update, or save this card.